Effects of Verapamil and Atenolol on Exercise Tolerance in 5,000 m Cross-Country Running: A Double-Blind Cross-Over Study in Normal Humans

Herbertsson, Pär; Fagher, Birger

doi:10.1097/00005344-199007000-00004

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One might also speculate whether the decrease in M/IG in patients treated with atenolol might be secondary to increased BMI due to impaired physical activity [45,46] or reduced energy expenditure [47,48] associated with blockage of the b-receptor. However, there was no significant relationship between changes in M/IG and body mass index in patients treated with atenolol in this study, and the association between changes in M/IG and MFVR was independent of changes in body mass index.…”

Section: Discussionmentioning

confidence: 99%

Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy

Olsen

Fossum

Høieggen

et al. 2005

Journal of Hypertension

View full text Add to dashboard Cite

As compared to atenolol, losartan treatment was associated with less peripheral vascular hypertrophy/rarefaction and higher insulin sensitivity. The relative change in MFVR and M/IG were inversely related, supporting the hypothesis that peripheral vascular changes in hypertension may induce insulin resistance. The ability of losartan to preserve insulin sensitivity may explain the lower incidence of new onset diabetes in patients treated with losartan in the LIFE study.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy

Olsen

Fossum

Høieggen

et al. 2005

Journal of Hypertension

View full text Add to dashboard Cite

show abstract

“…Interestingly, HDL-C decreased in the atenolol/bendroflumethiazide group but increased in the amlodipine/perindopril group in the recent Anglo-Scandinavian Cardiac Outcomes Trial [11,26], supporting the hypothesis that HDL-C is primarily reduced by thiazide treatment, adding to a negative effect of atenolol compared with a neutral or positive effect of losartan in the LIFE study. The larger decrease in HDL-C observed in patients randomized to atenololbased antihypertensive treatment may reflect the reduced peripheral circulation [27] and decreased physical activity known to be associated with beta-adrenergic receptor blockers [28,29].…”

Section: Discussionmentioning

confidence: 99%

Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study

Olsen

Wachtell²,

Beevers³

et al. 2009

Journal of Hypertension

View full text Add to dashboard Cite

show abstract

“…9 Alternatively, it is possible that patients in LIFE without preexisting vascular damage were especially sensitive to atenolol-induced vasoconstriction demasking subclinical peripheral vascular disease increasing the incidence of peripheral revascularization. However, it is also possible that patients randomized to atenolol were less active, 10 delaying clinical manifestation of peripheral vascular disease decreasing the incidence of peripheral revascularization.…”

mentioning

confidence: 99%

The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study

et al. 2006

View full text Add to dashboard Cite

The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study In the Losartan Intervention For End point reduction in hypertension (LIFE) study losartan-compared to atenolol-based antihypertensive treatment showed a tendency towards reducing peripheral revascularization (4.4 vs 57, P ¼ 0.07). This benefit was significant in the patients without peripheral vascular disease or without albuminuria at baseline (both Po0.01), suggesting that losartan may be particularly effective in preventing vascular damage in patients without preexisting vascular damage.In the LIFE study, the rate of myocardial infarction did not significantly differ between the treatment groups when losartan-compared with atenololbased treatment was administered to patients with hypertension and left ventricular hypertrophy (LVH) for a mean of 4.8 years. 1 On the other hand, in a subgroup of patients in the LIFE study, losartanbased, but not atenolol-based antihypertensive treatment, reduced carotid artery hypertrophy. 2 Furthermore, angiotensin II has experimentally been associated with development of atherosclerosis, 3 and blockage of the renin-angiotensin-aldosterone system may reduce atherosclerosis. 4 In the present analysis, we aimed to identify risk predictors for coronary and peripheral revascularizations in this large study and to investigate the effect of losartanbased compared with atenolol-based antihypertensive treatment on the incidences of coronary and peripheral revascularizations.The LIFE study design has been previously published. 5 9193 hypertensive patients aged 55-80 years with electrocardiographic (ECG) LVH were randomized to losartan-or atenolol-based antihypertensive treatment for a mean of 4.8 years. The revascularization analyses were pre-specified as part of the LIFE protocol. 5 Coronary revascularization included all coronary artery revascularization procedures (angioplasty, atherectomy and stent) and heart transplant. Peripheral revascularization included all noncoronary artery vascular surgeries and revascularization procedures (aortic aneurysm repair, carotid and peripheral revascularizations and amputations that were the result of arterial vascular insufficiency and diabetes mellitus). Revascularizations were reported by the investigators on endpoint report forms and verified by an independent endpoint classification committee consisting of two cardiology experts. All patients provided written informed consent, and the protocol was approved by all relevant ethical review committees.Data management and analysis were performed using SPSS 10.1 (SPSS, Chicago, IL, USA) software. Data are presented as mean7s.d. for continuous variables with normal distribution, median and inter-quartile range for continuous variables without normal distribution, and proportions for categorical variables. Only urinary albumin/creatinine ratio (UACR) was distributed non-normally and was transformed using logarithm of 1...

show abstract

Effects of Verapamil and Atenolol on Exercise Tolerance in 5,000 m Cross-Country Running: A Double-Blind Cross-Over Study in Normal Humans

Cited by 3 publications

References 0 publications

Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy

Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy

Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study

The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study

Contact Info

Product

Resources

About